AACC Survey Finds Nearly Half of All US Labs Still Do Not Have Supplies for Running COVID-19 Tests
|
By LabMedica International staff writers Posted on 30 Jul 2020 |

Illustration
A new survey of clinical laboratories in the US has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests.
The survey was conducted by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) which has presented its findings to the White House Coronavirus Task Force, calling on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.
As coronavirus cases in the US soar, the country’s labs have continued to work tirelessly to ramp up testing to help bring the pandemic under control. However, even though US labs are now performing an average of 800,000 COVID-19 tests per day, which is double the average daily number of tests performed in late May, labs in many areas are reporting delays of up to a week in getting test results back to patients. These delays render testing essentially useless in acute patient care and in contact tracing. The main cause of these crippling delays is the persistent shortage of testing and other essential supplies.
AACC conducted a survey to determine the full extent of these supply shortages and how they are changing as the pandemic progresses, in the hopes that this information can help guide the federal government’s response. AACC surveyed clinical labs across the US about this issue during three different time periods: May 1-24, June 1-5, and June 24-July 6. The results showed a troubling trend, namely that supply shortages have persisted over the last few months. In May, 58% of all labs surveyed reported problems getting supplies, a figure that only decreased to 46% by early July. Even more worrying was a rise in the number of labs that are unable to process all requested COVID-19 tests within a week because of supply shortages. In early July, 25% of respondents reported this problem, an uptick from 21% of respondents in May.
The specific supplies that labs have the most difficulty obtaining are COVID-19 test kits and the reagents, or chemicals, used to perform these tests. As of early July, 58% of labs reported problems getting test kits, while 46% reported problems getting reagents. 38% of labs also still reported problems getting the nasal swabs used to obtain patient samples for COVID-19 testing. In fact, out of all the items that respondents had difficulty obtaining in May, personal protective equipment (PPE) is the only one that was not in short supply in late June/early July. While 32% of labs had problems getting PPE in May, only 4% reported having this issue in the most recent survey.
“We at AACC are deeply concerned that clinical labs continue to struggle with obtaining the supplies needed to meet our nation’s COVID-19 diagnostic testing demands,” said AACC President Dr. Carmen Wiley. “While we recognize the difficulty the federal government is encountering with this pandemic, we urge the Task Force to use the data from AACC’s survey as a jumping off point to investigate these ongoing shortages, and to use the authority of the federal government to obtain and allocate these vital supplies.”
Related Links:
American Association for Clinical Chemistry (AACC)
The survey was conducted by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) which has presented its findings to the White House Coronavirus Task Force, calling on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.
As coronavirus cases in the US soar, the country’s labs have continued to work tirelessly to ramp up testing to help bring the pandemic under control. However, even though US labs are now performing an average of 800,000 COVID-19 tests per day, which is double the average daily number of tests performed in late May, labs in many areas are reporting delays of up to a week in getting test results back to patients. These delays render testing essentially useless in acute patient care and in contact tracing. The main cause of these crippling delays is the persistent shortage of testing and other essential supplies.
AACC conducted a survey to determine the full extent of these supply shortages and how they are changing as the pandemic progresses, in the hopes that this information can help guide the federal government’s response. AACC surveyed clinical labs across the US about this issue during three different time periods: May 1-24, June 1-5, and June 24-July 6. The results showed a troubling trend, namely that supply shortages have persisted over the last few months. In May, 58% of all labs surveyed reported problems getting supplies, a figure that only decreased to 46% by early July. Even more worrying was a rise in the number of labs that are unable to process all requested COVID-19 tests within a week because of supply shortages. In early July, 25% of respondents reported this problem, an uptick from 21% of respondents in May.
The specific supplies that labs have the most difficulty obtaining are COVID-19 test kits and the reagents, or chemicals, used to perform these tests. As of early July, 58% of labs reported problems getting test kits, while 46% reported problems getting reagents. 38% of labs also still reported problems getting the nasal swabs used to obtain patient samples for COVID-19 testing. In fact, out of all the items that respondents had difficulty obtaining in May, personal protective equipment (PPE) is the only one that was not in short supply in late June/early July. While 32% of labs had problems getting PPE in May, only 4% reported having this issue in the most recent survey.
“We at AACC are deeply concerned that clinical labs continue to struggle with obtaining the supplies needed to meet our nation’s COVID-19 diagnostic testing demands,” said AACC President Dr. Carmen Wiley. “While we recognize the difficulty the federal government is encountering with this pandemic, we urge the Task Force to use the data from AACC’s survey as a jumping off point to investigate these ongoing shortages, and to use the authority of the federal government to obtain and allocate these vital supplies.”
Related Links:
American Association for Clinical Chemistry (AACC)
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








